Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBITDA: 2010-2025

Historic EBITDA for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$26.6 million.

  • Northwest Biotherapeutics' EBITDA fell 22.02% to -$26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.4 million, marking a year-over-year decrease of 25.90%. This contributed to the annual value of -$83.7 million for FY2024, which is 26.83% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' EBITDA stood at -$26.6 million, which was down 38.38% from -$19.2 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' EBITDA registered a high of -$10.0 million during Q3 2021, and its lowest value of -$26.6 million during Q3 2025.
  • Its 3-year average for EBITDA is -$18.7 million, with a median of -$18.3 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' EBITDA was 79.01% (2021), while the steepest drop was 619.51% (2021).
  • Northwest Biotherapeutics' EBITDA (Quarterly) stood at -$10.7 million in 2021, then plummeted by 70.27% to -$18.2 million in 2022, then grew by 16.70% to -$15.1 million in 2023, then slumped by 67.90% to -$25.4 million in 2024, then decreased by 22.02% to -$26.6 million in 2025.
  • Its EBITDA stands at -$26.6 million for Q3 2025, versus -$19.2 million for Q2 2025 and -$21.3 million for Q1 2025.